Palatin Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $16.7M
- Price
- $9.40
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.11%
- Volume
- 6.4K
About
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Quick stats
Shares outstanding1.8M
Computed float1.7M
Float / shares95.1%
Cash runway (months)3.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000911216
Websitehttps://palatin.com
AI Summary
AI-generated1/6
standardmixedearnings
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin reported fiscal 2026 collaboration and license revenue of $13.2 million versus no revenue a year ago, driven by the Boehringer Ingelheim ($9.4M) and Altanispac Labs ($3.8M non-cash) agreements.
The fiscal-year net loss narrowed to $8.4 million ($2.96 per share) from $17.3 million, while R&D spend fell to $12.4 million as MC4R program activity shifted timing.
Cash of $7.5 million at June 30, 2026 is not expected to fund operations for at least twelve months; the company states substantial doubt exists about its ability to continue as a going concern and will need additional financing.
Pipeline progress includes MC4R peptide candidates (PL1000, PL2000) targeting Phase 1 starts in 2027, plus PL8177 and a diabetic nephropathy MCR agonist available for partnering.
Red flags
- Going-concern warning: $7.5M cash insufficient to fund operations for at least twelve months
- Future development milestones contingent on raising additional capital on acceptable terms
- Heavy reliance on equity/warrant sales ($18.5M financing inflows in FY26) implies ongoing dilution
- Clinical catalysts not until 2027, extending the funding gap